A. Heller

T-Cell Heterogeneity in Baseline Tumor Samples: Implications for Early Clinical Trial Design and Analysis

F. Gaire, K. Korski, J. Brouwer-Visser, 2022, Frontiers in Immunology.

Thymidine Metabolism as a Confounding Factor for 3′-Deoxy-3′-18F-Fluorothymidine Uptake After Therapy in a Colorectal Cancer Model

J. Griffiths, R. Sinkus, K. Schäfers, 2018, The Journal of Nuclear Medicine.

A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy

J. Möcks, E. Felip, S. Cedrés, 2008, Clinical Cancer Research.

Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: FISH results.

J. Möcks, J. Baselga, E. Felip, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation.

Volker Schmid, S. Stritt, B. Bossenmaier, 2014, Chemistry & biology.

Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes.

M. Manns, T. Greten, D. Pardoll, 2002, Journal of immunological methods.

Recombinant Technology Peptide – h 2-microglobulin – MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC – Ig complexes

M. Manns, T. Greten, D. Pardoll, 2002 .

Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +/- erlotinib (TALENT)

G. Sauter, J. Moecks, U. Gatzemeier, 2005 .

Thymidine Metabolism as a Confounding Factor for 3′-Deoxy-3′-18F-Fluorothymidine Uptake After Therapy in a Colorectal Cancer Model

J. Griffiths, R. Sinkus, K. Schäfers, 2018, The Journal of Nuclear Medicine.